ChemicalBook > CAS DataBase List > Mirikizumab

Mirikizumab

Product Name
Mirikizumab
CAS No.
1884201-71-1
Chemical Name
Mirikizumab
Synonyms
Mirikizumab;Mirikizumab (anti-IL-23);Research Grade Mirikizumab;Research Grade Mirikizumab(DHJ63105)
CBNumber
CB78081055
Formula Weight
0
MOL File
Mol file
More
Less

Mirikizumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Mirikizumab Chemical Properties,Usage,Production

Uses

Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease[1][2].

in vivo

Mirikizumab (7.5 mg/kg, i.p., administered at 9, 16, and 32 hours) exhibits anti-inflammatory activity in an acute systemic mouse model[2].

Animal Model:Acute systemic C57BL/6 mice model
Dosage:7.5 mg/kg
Administration:Intraperitoneal injection (i.p.), dosing time of 9, 16, 32 h
Result:Inhibited human IL-23-induced mouse IL-17A, IL-17F, and keratin-16 mRNA production in an acute systemic mice model.

References

[1] Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.
[2] Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. DOI:10.1124/jpet.122.001512

Mirikizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Mirikizumab Suppliers

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9766
Advantage
58

1884201-71-1, MirikizumabRelated Search:


  • Mirikizumab
  • Research Grade Mirikizumab(DHJ63105)
  • Research Grade Mirikizumab
  • Mirikizumab (anti-IL-23)
  • 1884201-71-1